Effective treatment relies on the accurate identification of pathogens. However, standard of care methods such as blood culture often fail to provide results quickly enough for prompt early treatment. This delay in identifying pathogens negatively affects patient outcomes and increases the risk of antimicrobial resistance (AMR) due to the extended use of broad-spectrum antibiotics.

InfectID™-BSI addresses the limitations of standard of care by using a direct molecular identification technique. While standard of care, including blood culture, remains necessary, InfectID™-BSI provides results within hours, enabling clinicians to make informed decisions for targeted therapy sooner. ​